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Abstract
Friedreich’s ataxia is an inherited neurodegenerative disease caused by frataxin deficiency.
Frataxin is a conserved mitochondrial protein that plays a role in Fe-S cluster assembly in
mitochondria. Fe-S clusters are modular cofactors that perform essential functions
throughout the cell. They are synthesized by a multi-step and multi-subunit mitochondrial
machinery that includes a scaffold protein Isu for assembling a protein bound Fe-S cluster
intermediate. Frataxin interacts with Isu, iron, and with the cysteine desulfurase Nfs1 that
supplies sulfur, thus placing it at the center of mitochondrial Fe-S cluster biosynthesis.
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Introduction
Friedreich’s ataxia is an inherited disease characterized by progressive symptoms of ataxia and
sensory loss, often leading to gait impairment and the need for a wheelchair. A progressive and
sometimes lethal cardiomyopathy is another feature and in some cases diabetes mellitis is
associated. At the pathological level, degenerative changes affect certain large sensory neurons,
heart cells and islet cells, thus involving a unique target tissue distribution (1). The gene was
identified by genome mapping of affected kindreds, and the encoded protein, frataxin, is decreased
in affected individuals most often due to a GAA repeat in the first intron of the gene (2). The protein
is found primarily in mitochondria (3). Human frataxin is synthesized on cytoplasmic ribosomes
with a mitochondrial targeting sequence that mediates organelle targeting and is subsequently
removed by proteolytic processing steps in the mitochondrial matrix (4-7). Deficiencies of aconitase
and other mitochondrial iron-sulfur (Fe-S) proteins occur as first noted in cardiac biopsies of
affected individuals (8). Fe-S clusters are modular cofactors consisting of iron and sulfur, most often
anchored by bonds joining cysteine sulfur atoms in the polypeptide chain of a protein and iron atoms
of the cluster. They perform essential and diverse biochemical functions (electron transfer in cellular
respiration, substrate interaction, biological signal transduction among other functions), and their
biogenesis is catalyzed by a multisubunit machinery (9). Frataxin has been a subject of intense
study with contributions from many disciplines: structural biology, cell biology, genetics of model
organisms, evolutionary biology, and medicine. A picture is emerging of a direct role of frataxin in
the complex and highly conserved machinery of Fe-S cluster biogenesis in mitochondria. Additional
functions may be mediated by direct frataxin-iron effects or by other protein-protein interactions.

Frataxin Evolution
Frataxin is highly conserved throughout evolution, being present in humans, plants, flies, worms,
and bacteria (proteobacteria but not archaebacteria) (10). Some hints about frataxin function can be
gleaned from the evolutionary record. Three different bacterial operons have been identified capable
of mediating Fe-S clusters assembly: nif, suf and isc. The nif operon is specialized for high volume
biosynthesis needed to support nitrogenase synthesis during diazotropic growth of some organisms
(e.g. Azotobacter vinlandii). The suf operon is specially adapted for Fe-S cluster synthesis in
conditions of iron starvation and oxidative stress. Finally the isc operon handles housekeeping Fe-S
cluster biogenesis (9). Although not found on any of these operons, frataxin is strongly associated
with the isc operon. It appeared in proteobacteria about the time that the specialized chaperones
3
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hscA and hscB appeared on the isc operon. A frataxin homolog was subsequently lost in this
phylogenetic lineage on two separate occasions, coinciding with loss of hscA and hscB. Frataxin’s
appearance in eukaryotes occurred about the time of the endosymbiotic event creating mitochondria
from the purple bacterial ancestor, and it was probably acquired by mitochondria together with
other components of the isc operon (10). This notion of co-evolution of frataxin and Fe-S assembly
components of the isc operon is supported by studies of primitive eukaryotes that lack typical
mitochondria. In Trichomonas vaginalis, a unicellar parasite, a modified and stripped-down
organelle called the hydrogenosome performs Fe-S cluster assembly and contains a frataxin
homolog able to complement the phenotypic defects of a yeast mutant lacking its own frataxin (11).
An even more severe case of organelle simplification is presented by mitosomes. These are
rudimentary organelles of obligate intracellular parasites called microsporidia, and they lack
respiratory complexes or mitochondrial DNA. Virtually all that remains are a few components
recognizable for their homology to Fe-S cluster assembly components (e.g. Isu, Nfs1, Hsp70
homologs) and frataxin (12). The co-retention of frataxin with these very few other components
involved in Fe-S cluster assembly in the mitosome emphasizes their close functional relationship.

Mitochondrial iron accumulation
In Saccharomyces cerevisiae, Yfh1 is the yeast frataxin homolog, and the initial studies of the

∆yfh1 deletion strain described a pleiomorphic phenotype. The mutant exhibited constitutive
upregulation of the cellular iron uptake system and tremendous accumulation of iron in
mitochondria (13). The accumulated iron appeared as dense aggregates in unstained electron
micrographs. Chemical analyses revealed the accumulated iron was in the form of ferric phosphate
micelles (14). Many additional studies have established a close association of the mitochondrial iron
accumulation phenotype and deficiency of Fe-S clusters. Cellular depletion studies in which Yfh1
was put under control of a regulated promoter and turned off recapitulated the phenotypes of
deficient Fe-S cluster proteins and mitochondrial iron accumulation. If the promoter was turned on
again, Fe-S clusters were restored and the accumulated iron returned to a normal distribution (15).
Other mutants of the mitochondrial Fe-S cluster assembly pathway were similarly associated with
this iron homeostatic phenotype (ssq1, jac1, nfs1, others). In human cells, mitochondrial iron
accumulation has also been observed, both in tissues from Friedreich’s patients (e.g. heart, dorsal
root ganglia) and in cultured cells engineered to exhibit stable frataxin deficiency (16). Thus low
level frataxin is associated with mitochondrial iron accumulation and Fe-S cluster deficiency in both
human and yeast cells, indicating a remarkable degree of conservation of the iron homeostatic
4
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machineries (17). The presumption is that there exists a conserved regulatory Fe-S cluster protein
or proteins mediating these effects. At this time however, although an unusual Fe-S cluster
(liganded by glutathione and glutaredoxins) has been found to mediate control of cellular iron
uptake in yeast (18,19), the controlling protein(s) for mitochondrial iron uptake or accumulation has
not been identified for any species, and so the latter piece is still missing from our understanding.

FeFe-S cluster assembly in mitochondria:
mitochondria Frataxin has been found in mitochondria of virtually all
eukaryotes using biochemical and microscopic tools to ascertain its subcellular location. Similarly,
homologs of the other Isc Fe-S cluster assembly components have been found in mitochondria (20).
The steps and components involved in the biogenesis of Fe-S cluster proteins in mitochondria are
quite similar to those in bacteria. The process can be understood in terms of the central role of
scaffolds as first shown by Dennis Dean and now well established (21). An Fe-S cluster intermediate
is first formed on the scaffold protein Isu and then transferred to apoproteins (Fig. 1). Many steps
must occur in a coordinated fashion for proper Fe-S cluster synthesis on Isu. The sulfur for Fe-S
clusters originates from cysteine via the action of Nfs1, a pyridoxal phosphate containing cysteine
desulfurase. In eukaryotes, Nfs1 must be assembled with Isd11, a small accessory subunit of
unknown function (22,23). The sulfur is probably transferred to Isu from the Nfs1 active site as a
persulfide. The source of the iron for the Isu intermediate is unclear, although a role for
mitochondrial carrier proteins Mrs3 and Mrs4 in yeast (mitoferrin in humans) has been proposed
(24). Frataxin may play a role here and has been shown to genetically interact with the
mitochondrial carrier proteins. This is shown by the exacerbated slow growth and mitochondrial
iron starvation in the combined ∆mrs3∆mrs4∆yfh1 mutant (25). Other components implicated at
this stage are Arh1 and Yah1 (adrenodoxin reductase and adrenodoxin in humans), which are
needed to provide reducing equivalents in an electron transfer chain, although the substrate
requiring reduction has not been defined (26). The Isu protein appears to be conserved in the
context of primary sequence and function, and structural information exists for a few bacterial
homologs. Key features are three critical cysteines and an aspartate that bind the cluster
intermediate probably on each subunit of the Isu dimer (27).

Following formation of the Isu scaffold intermediate, several additional components are required
for transfer of the intermediate to recipient apoproteins. The scaffold Isu displays an interaction site
consisting of the tripeptide sequence, PVK, and this mediates binding to the Hsp70 chaperone (Ssq1
in yeast and Ssc1 in humans) (28,29). This interaction is modulated by the ATP hydrolysis cycle in
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conjunction with accessory proteins Jac1 and Mge1 (30).. A monothiol glutaredoxin is also implicated
here (31).. The proteins destined to become Fe
Fe-S
S cluster proteins in mitochondria are translated on
cytoplasmic ribosomes as precursor proteins with mitochondrial targeting sequences. Upon import
into mitochondria, the unfolded precursors are subjected to various processing steps that remove the
targeting sequences (32),, and the mature apoproteins thus generated become substrates for transfer
of Fe-S clusters from Isu (Fig. 1).

Fig. 1: Scheme showing role of yeast frataxin (Yfh1) in mitochondrial Fe
Fe-S
S cluster assembly. The
mitochondrion is shown as an oval bounded by a double membrane. Yfh1 is shown as a helix-sheet
helix
sandwich
(green and tan). A. Mitochondrial carriers Mrs3 and Mrs4 (box) play a role in transfer of iron in some form
(Fe-X)
X) across the mitochondrial inner me
membrane. Cysteine (Cys-SH)
SH) enters mitochondria and is acted on by
the enzyme Nfs1 and its accessory protein Isd11 to provide sulfur for Fe
Fe-S
S clusters. Electrons or reducing
equivalents are provided by the reductase Arh1 in the membrane and the associated ferredoxin
fe
Yah1. Yfh1
physically interacts with Nfs1, Isd11, and Isu. B. The Fe
Fe-S
S cluster intermediate (red diamond) is assembled on
the scaffold Isu, which interacts with Nfs1, Isd11 and Yfh1. Another complex is formed by Isu and Ssq1, Jac1,
Mge1 with the binding
inding site being provided by the PVK tripeptide on Isu1. Grx5 acts at this step. C. The
precursor proteins (squiggly black lines) are nuclear encoded, translated on cytoplasmic ribosomes, and
targeted to mitochondria and imported in unfolded state. After proteolytic processing they are folded and
acquire the Fe-S
S cluster cofactor (red diamond) by action of the chaperones and glutaredoxin.
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Epistasis and placement of Yfh1 within the pathway of Fe-S cluster assembly
The central component in Fe-S cluster assembly in mitochondria is the Isu scaffold. In order to
begin to address the function of frataxin, it was important to determine if frataxin acts before Isu, in
formation of the Fe-S cluster intermediates, or after Isu, in the transfer of the Isu intermediates to
apoproteins. In one approach to this problem, a form of metabolic labeling was devised in which
radioactive iron was added to growing yeast cells, and the radiolabeled Fe-S cluster Isu
intermediate was recovered by immunoprecipitation (33). This approach was combined with
promoter swaps to produce cellular depletion of one or another of the assembly component(s) prior
to iron labeling and Isu recovery. A reduction in iron labeling of Isu would indicate decreased
formation of Fe-S cluster intermediates. In that case, the depleted component was placed upstream
of Isu, because it was necessary for intermediate formation. In the case of increased iron labeling of
Isu, the component placed downstream of Isu, because it was needed for transfer of the Isu clusters
to recipient apoproteins. Using this assay design, Nfs1, Arh1, Yah1 were placed upstream, and Ssq1,
Jac1, and Grx5 were placed downstream of Isu in the Fe-S cluster assembly process. Frataxin was
placed upstream, because frataxin depleted cells failed to efficiently form the radiolabeled Isu
intermediate (34).

A completely independent set of observations led to a similar conclusion. The manganese
superoxide dismutase (MnSod), the dismutase of the mitochondrial matrix, was found to incorporate
iron instead of manganese in some settings, with concomitant inactivation of the enzyme. For
example, some of the Fe-S cluster assembly mutants with a mitochondrial iron accumulation
phenotype were associated with MnSod mismetallation. Specifically, these mutants, such as ssq1
and grx5, belonged to Isu downstream events in transfer of Fe-S cluster intermediates to
apoproteins (35). By contrast, although frataxin mutants (∆yfh1) dramatically accumulated iron in
mitochondria, the iron was not available for (mis)incorporation into MnSod (36). Similarly Isu
mutants (depletion or dominant negatives) were also not associated with MnSod inactivation (35).
These data suggest frataxin should be grouped with Isu in the upstream part of the Fe-S cluster
biogenesis pathway and distinguished from Ssq1 and Grx5. Although mismetallation is an aberrant
situation, these observations may point to a physiological role of frataxin in modulating bioavailable
iron pools in mitochondria.
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Effects of frataxin in promoting Fe-S cluster assembly in mitochondria
Two experiments are presented to illustrate the role of frataxin in promoting Fe-S cluster
assembly in mitochondria. In the first experiment, mitochondria were isolated from wild-type or

∆yfh1 strains. New synthesis of Fe-S clusters in the isolated organelles was examined by providing
35S-cysteine

as a source of sulfur. In the wild-type, radioactive sulfur was incorporated into a pool of

apoaconitase by the mitochondrial Fe-S cluster machinery. Synthesis of new clusters was also
detected by labeling of imported ferredoxin, and these could be distinguished by signals on a native
gel (Fig. 2A, left panel; Fig. 2B, lanes 1 and 2). In the mutant, however, no such labeling occurred,
indicating failure to make Fe-S clusters (Fig. 2A, middle panel; Fig. 2B, lanes 5 and 6).
Subsequently, frataxin was imported into the ∆yfh1 mutant mitochondria and the mitochondria
were recovered by centrifugation. When a similar

35S-cysteine

labeling experiment was performed,

the mutant mitochondria demonstrated restored ability to make Fe-S clusters on both aconitase and
imported ferredoxin (Fig. 2A, right panel; Fig. 2B, lanes 7 and 8). Thus a very small amount of
frataxin (estimated less than one picomole) imported into isolated ∆yfh1 mitochondria even without
iron addition was able to rapidly (in less than 10 minutes) restore Fe-S cluster synthesizing activity.
This effect in isolated mitochondria shows that everything is present in mitochondria for Fe-S
cluster formation and that a small quantity of frataxin activates or mediates the process (25).

In the second experiment, a more reductionist approach was taken with purified proteins. Isu was
expressed and purified from bacteria in the apoprotein form, without any cluster. If Isu was
incubated with elemental iron and sulfur, a small amount of Fe-S cluster intermediate could be
detected as shown by appearance of the characteristic absorption spectrum (Fig. 3, tracing B). In a
parallel incubation, Isu was added to elemental sulfur and iron loaded frataxin monomer instead of
elemental iron alone. The absorbance tracing (Fig. 3, tracing A) followed over time showed
tremendous facilitation in the presence of frataxin. In this experiment, Drosophila frataxin was
used because of its greater stability, and a D37A mutant of yeast Isu was used to trap and stabilize
the intermediate on Isu (37). A similar assay showed activity of human frataxin in facilitating Fe-S
cluster formation on the human Isu scaffold protein (38). These experiments with purified
components demonstrate that frataxin possesses the ability to facilitate Fe-S cluster formation on
Isu.
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Fig. 2: Imported frataxin (Yfh1) restores Fe
Fe-S
S cluster assembly in isolated yeast mitochondria. A. Wild-type
Wild
mitochondria (left panel) synthesize Fe
Fe-S
S clusters on endogenous Apoaconitase and imported ApoYah1.
Mutant ∆yfh1 (middle panel) fail to synthesize clusters. Following Yfh1 precursor import mutant ∆yfh1
mitochondria (right panel) now synthesize clusters. B. Mitochondria were isolated from wild-type
wild
or ∆yfh1
strains. Full length yeast frataxin (produced and radiolabeled on methionine and cysteine in the polypeptide)
was imported (18 degrees, 10 min, lanes 3, 4, 7, 8) and mitochondria were recovered by centrifugation. In the
second stage, 35S-cysteine
cysteine and ferredoxin precursor Yah1 were imported 10 min, 30 degrees). The
mitochondria were recovered and the
he matrix fraction analyzed by a native gel and autoradiography (lanes 11
8). The imported Yfh1 labeled on the polypeptide is visible on the gel. The imported ferredoxin labeled on the
sulfur of the Fe-S is visible in ∆yfh1
yfh1 mitochondria only following Yfh1 import (lanes 5, 6). Similarly,
endogenous aconitase labeled on its Fe
Fe-S cluster is visible in ∆yfh1 only following Yfh1 import (lanes 5, 6) (25).
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Fig. 3: Frataxin facilitates the rate and efficiency of Fe
Fe-S
S cluster formation on Isu scaffold. Yeast Isu was
expressed and purified from
rom bacteria in the apoprotein form (D37A mutated form of Isu1). Mature drosophila
frataxin Dfh was likewise expressed and purified from bacteria. The reactions contained 100 µM Isu scaffold.
To this was added sulfur (2.4 mM Na2S) and iron (100 µM ferrous ammonium sulfate) (tracing B) or ironiron
frataxin (100 µM of Dfh-iron
iron monomer) (tracing A). The formation of cluster on Isu was followed by absorbance
at 426 nm. Time dependence data from tracing A was fit with a rate equation for a first order process (panel C)
(37).

Frataxin structures
Structures have been obtained
btained for yeast (39), human (40) and bacterial (41) frataxins. They are
strikingly alike, characterized by an alpha
alpha-beta
beta sandwich motif creating the two protein planes. The
α-helical plane consists of two parallel (N and C terminal) alpha helices, and the β-sheet plane
consists of five anti-parallel
parallel beta sheets; a sixth and possibly seventh strand intersect the planes
depending on the species (42).. The structure and length of the respective N
N-termini
termini vary among
orthologs, while the unstructured C
C-termini,
i, also of variable length, help control protein stability
(43).. A negatively charged surface is created by clustering of contiguous acidic residues contributed
c
by portions of helix 1 and beta sheet 1. Although the individual residues are not always conserved,
all known frataxins are characterized by the presence of such an acidic surface. A second conserved
structural feature is a neutral flat area on the beta sheet surface, with more hydrophobic towards
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the center and more hydrophilic towards the periphery. This region contains a number of perfectly
conserved residues that appears to be well suited to mediate interaction with a protein partner.

Isu interaction
A functional relationship of frataxin and Isu was initially suggested by genetic experiments
showing synthetic lethality of ∆yfh1 (YFH1 gene deleted) and ∆isu1 (deletion of one of two
homologous ISU genes causing lowered levels of Isu) (44). Physical interactions between frataxin
and Isu were subsequently demonstrated in pull-down experiments from mitochondrial lysate.
Interestingly the pull-down of Yfh1 by Isu, or reciprocally of Isu by Yfh1, was dependent on iron
addition to the buffer (50 µM ferrous ammonium sulfate), and then inhibited by the presence of the
metal chelator EDTA (45). The clearest demonstration of the importance of frataxin-Isu interaction
in Fe-S cluster assembly was provided by careful analyses of mutant alleles of frataxin that failed to
interact. A frataxin mutant (N122A/K123T/Q124A) was constructed by alteration of conserved
surface exposed residues of the strand 3 in an area predicted to mediate protein interactions
(46)(Table 1, column 1). These mutations did not interfere with protein expression or stability, and

in vitro studies showed no effect on iron binding. However, interaction with Isu was severely
impaired as assessed by pull-down from mitochondrial lysates onto immobilized Yfh1-His6. In these
experiments, the affinity of frataxin binding to Isu was markedly decreased from about 1 µM for the
wild-type to a number greater than 12 µM for the mutant. Experiments with purified Yfh1 and Isu1,
as distinguished from lysate containing these and other proteins, also showed the interaction and
the reduced affinity of the mutant, confirming that the mutational effect was direct. Importantly, in

vivo experiments performed with the same yfh1 mutant demonstrated reduced Fe-S cluster protein
activities and increased iron accumulation in mitochondria. The N122K mutant similarly was
associated with decreased Isu interaction and decreased Fe-S cluster enzyme activities. The N122K
mutation corresponds to N146K in the human ortholog and has been associated with Friedreich’s
ataxia. The wild-type and mutant proteins placed under control of a regulated promoter and
expressed over a wide range of concentrations confirmed mutant phenotypes occurred over a wide
range of expression levels (46). Other mutations were constructed that altered amino acids in
exposed areas of the beta sheet (Q129A in strand 4, W131A in strand 4 and R141A in strand 5).
These mutations were examined in vitro and in vivo, and they too showed decreased frataxin-Isu
interaction and deficiency of Fe-S cluster proteins (47) (Table 1, column 2, Fig. 4). The studies with
mutant alleles were especially informative because they avoided many of the secondary phenotypes
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associated with the yfh1 deletion. The conclusion from these studies is the interaction between
frataxin and Isu is required for Fe-S cluster assembly in the mitochondria.

Table 1: Amino acids with effects on Yfh1Yfh1-Isu
interaction and FeFe-S cluster proteins
structure
amino acid no.
Ref 1 Ref 2 Ref 3
beta 1
D101
x
beta 1
E103
x
beta 3
N122
x
beta 3
K123
x
beta 3
Q124
x
beta 4
Q129
#1
beta 4
W131
#2
beta 5
R141
#3
Ref 1 (46): Triple Yfh1 mutant N122A/K123T/Q124A, diminished Isu interaction, low aconitase and
succinate dehydrogenase, iron accumulation
Ref 2 (47): Single mutants #1 Q129A #2 W131A #3 R141A, diminished Isu interaction, low aconitase
Ref 3 (55): Double mutant D101A/E103A, no interaction with Isu, aconitase decreased

Iron binding
Frataxins interact with iron in vitro, although not in the manner of typical iron binding proteins.
Binding is relatively low affinity, occurs on the protein surface rather than in a cavity, and is
mediated primarily by carboxylic amino acids rather than cysteines and histidines (48). Analysis of
iron interaction with yeast frataxin monomer showed two ferrous atoms binding with affinity of 2.5
to 5 µM as high spin iron. Chemical shifts and line broadening induced by exposure of

15N-labeled

yeast frataxin to iron (ferrous iron under anaerobic conditions) further defined iron binding residues
as primarily carboxylate-containing amino acids in the helix 1-strand 1 region (39,49). Studies with
other frataxin orthologs gave similar results although with some variation in iron binding
stoichiometry and affinity (human bound 6 atoms with Kd 12-55 µM (38), E. coli bound 2 atoms with
Kd 4 µM (50), Drosophila bound 1 atom with Kd 6 µM (37)). Mutagenesis studies performed with the
objective of correlating in vitro iron binding and in vivo function have been problematic in part
because of the redundant nature of the iron binding site(s) distributed over a surface and mediated
by multiple iron binding amino acids. In addition, various effects of iron binding to frataxin have
been observed, some of which may be physiologically important and some of which may not be
relevant.
12 DIGITALCOMMONS@WSU | 2010
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Some frataxins oligomerize when exposed to iron. Exposure of yeast or E. coli frataxins to 20-fold
molar excess of elemental iron in the absence of competing cations induced oligomerization, but this
did not occur with the human protein (51).. Mutation of three carboxylates D86, E90, and E93 to
alanine completely abrogated iron dependent oligomerization of the yeast protein (Table 2, column
1, Fig. 4). This triplee mutant, when tested in vivo, showed no deleterious effects on Fe-S
Fe cluster
protein activities and iron homeostasis, even when expressed at low levels (52). Thus frataxin
oligomerization is probably
bly not required for Fe
Fe-S
S cluster synthesis. Other mutations were tested in
both in vitro and in vivo assays within yeast. A D79A/D82A mutation abrogated ferroxidase activity.
The D79A/D82A or E93A/D97A/E103A mutants showed decreased frataxin
frataxin-iron interactions in

vitro, and both of these mutant alleles were associated with increased oxidant sensitivity and
decreased life span in vivo. However, these mutations had no effect on aconitase activity and no
effect on mitochondrial iron accumulation (53) (Table 2, column 2), and thus they are probably not
important for Fe-S
S cluster biogenesis.
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Fig 4: Frataxin ortholog sequence alignment and Yfh1 structure showing locations of mutations with effects
on iron binding and/or Isu binding. A. Se
Sequence alignment of yeast, human and E. coli frataxin using
ClustalW with structural features on top. The colored amino acids have been studied by mutagenesis and are
implicated in iron interaction (red), or Isu interaction (blue). B. Solution structure of monomeric apo-Yfh1
apo
(PDB ID# 2GA5) with residues involved in Isu binding identified in blue. C. Solution structure of monomeric
apo-Yfh1
Yfh1 with residues involved in Fe binding identified in red (39).
(39)

By contrast, mutation of four acidic residues D86/E89/D101/E103 to alanine was more deleterious
for Fe-S
S clusters: aconitase was decreased to 30% of wild
wild-type
type levels and mitochondrial iron
accumulation occurred. Iron binding to this mutant frataxin was not measured directly, although
iron dependent Isu interaction in mitochondrial lysate was markedly decreased (54) (Table 2,
column 3). Another set of experiments
riments illustrates the problem of redundancy in the acidic iron
binding sites. A yeast frataxin mutant D86/E90/E93 gave no in vivo phenotype (compared with wildwild
type), regardless of the frataxin expression level. The D101/E103 mutant displayed a modest
phenotype
enotype with moderately lower aconitase. However, the combined mutant exhibited a severe
phenotype with growth inhibition and 40% residual aconitase activity. Iron binding affinity of this
combined mutant protein was reduced by tryptophan fluorescence titr
titration
ation but was not abolished
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(55) (Table 2, column 4). Interestingly, the frataxin-Isu iron dependent interaction tested with
purified proteins was abrogated by the D101/E103 or the combined D886/E90/E93/D101/E103
mutations (55). We determined mutational effects of amino acids that showed strong interactions
with Fe2+ in an NMR study with

15N–labeled

Yfh1. Two possible iron binding sites were identified,

one site consisting of D68/E93/H95 (site 1) and the other consisting of D101/E103 (site 2). Mutation
of site 1 residues to alanine had no discernable effect on in vivo phenotypes, mutations of site 2 had
a very mild effect (aconitase 90%), although iron binding stoichiometry for these mutants was
decreased such that only one iron bound per molecule. Combined mutations of site 1 and site 2
showed no iron binding by ITC or NMR titrations, and the in vivo phenotypes were quite severe,
with aconitase of 37%, slow growth, and mitochondrial iron accumulation. These data show a
correlation of frataxin iron binding and Fe-S cluster assembly activity i.e. the mutated iron binding
sites were correlated with severely compromised Fe-S cluster assembly activity (Table 2, column 5,
manuscript in preparation).

TABLE 2: Yfh1 iron binding amino acids and their effects on FeFe-S cluster
assembly.
structure
alpha 1
alpha 1
alpha 1
alpha 1
alpha 1
alpha 1
alpha 1
alpha 1–beta 1
beta 1
beta 1

amino
acid no.
D79
D82
D86
E89
E90
E93
H95
D97
D101
E103

Ref 1

Ref 2

Ref 3

Ref 4

Ref 5

x
x

#1

#1

#1
#1
x
x
x

#1
#1

#2

#1
#1

#2
#2

x
x

#2
#2

#2
#2

Ref 1 (52): Triple Yfh1 mutant D86A/E90A/E93A , no oligomerization in response to iron exposure in vitro,
normal Isu interaction, no Fe-S deficit, no iron accumulation
Ref 2 (53): Double Yfh1 mutant #1 D79A/D82A, low ferroxidase, oxidant sensitivity, normal aconitase, no
iron accumulation. Triple Yfh1 mutant #2 E93A/D97A/E103A, oxidant sensitivity, normal aconitase, no iron
accumulation .
Ref 3 (54): Quadruple mutant D86A/89A/E101A/E103A , decreased iron dependent Isu interaction, low
aconitase, iron accumulation .
Ref 4 (55): Triple Yfh1 mutant #1 D86/A/E90A/E93A, decreased iron binding affinity, normal aconitase, no
iron accumulation. Double mutant #2 D101A/E103, decreased iron binding affinity, mild low aconitase, no
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growth defect. Combined mutant #1 and #2: D86A/E90A/E93A/D101A/E103A , decreased iron binding affinity,
lower aconitase, slow growth.
Ref 5 (unpublished): Triple Yfh1 mutant #1 D86A/E90A/E93A, decreased iron binding stoichiometry,
normal aconitase, no iron accumulation. Double mutant #2 D101A/E103A, decreased iron binding
stoichiometry, slight decrease aconitase, no growth defect. Combined mutant #1 and #2
D86A/E90A/E93A/E101A/E103A, no iron binding in vitro, decreased aconitase, iron accumulation, slow
growth.

How frataxin might work
In summary, frataxin interacts with the Fe-S cluster assembly scaffold protein Isu using frataxin’s
beta sheet surface. It also interacts with iron via surface carboxylates of the helix 1-strand 1 area.
Furthermore the frataxin-Isu interaction is iron dependent. Various in vitro assays have
demonstrated these interactions and in vivo experiments with mutant alleles have shown the
importance of these interactions for Fe-S cluster formation. Frataxin might work as a metal
chaperone similar to copper chaperones involved in copper trafficking and copper metallation of
proteins. Copper chaperones function by high affinity interactions with copper and with recipient
proteins. Copper is bound to the chaperone, then liganded between chaperone and target protein,
and finally handed off to the target protein. The copper thus is never free in solution and is targeted
to its correct destination in the cell by the protein-protein interactions between chaperone and
target (56). Frataxin might work in a similar fashion by transiently binding iron in mitochondria,
interacting with Isu in an iron dependent fashion, and finally transferring protein bound iron to Isu.
However, the affinity of frataxin for iron is relatively low and coordination incomplete, with the
carboxylate binding sites being completed by water molecules. The driving force and mechanism of
metal transfer to recipients also might be different than for the copper chaperones. A prediction of
this model is that the iron liganding sites should overlap or be contiguous with the Isu binding sites.
This may be the case especially for the iron binding site on the strand 1 consisting of the conserved
D101/E103 residues. Biochemical data suggest frataxin facilitates iron use for Fe-S cluster
formation on Isu (38) (Fig. 3). Other functions in mitochondrial iron trafficking are also possible. In
line with the iron chaperone idea, frataxin might bind iron and bind to other proteins, thereby
targeting the metal for delivery to aconitase (57), ferrochelatase (14,39) and succinate
dehydrogenase (58). Iron specific activities of frataxin have also been suggested, and some bypass of
frataxin mutant phenotypes including Fe-S cluster deficiencies has been observed as a result of
forced expression of mitochondrial ferritin (59).
16 DIGITALCOMMONS@WSU | 2010

Frataxin and mitochondrial Fe-S cluster biogenesis | Timothy Stemmler, et. al

Alternatively, the function of frataxin in Fe-S cluster biogenesis might be primarily a regulatory
one. The iron dependent frataxin-Isu interaction might signal formation of a protein complex for
creation of the Fe-S intermediate on Isu. Of note, pull down experiments from mitochondria with
yeast frataxin as bait yielded not only Isu, but also Nfs1 (45) and Isd11 (46), the functional cysteine
desulfurase complex responsible for providing sulfur for iron-sulfur. Perhaps the data are pointing
to the existence of a multi-subunit complex consisting of frataxin, Isd11-Nfs1, and Isu. Such a
complex would be well situated to mediate formation of the Isu bound Fe-S cluster intermediate.
Iron and sulfur are toxic intermediates, and their insertion into Fe-S clusters must be controlled to
avoid toxicity. Frataxin might regulate the flux of these key intermediates, permitting delivery of
enough for physiologic Fe-S cluster formation and not so much as to create iron and/or sulfide
toxicity. The source of iron and its biological form are not well understood. The sulfur generated by
the action of Nfs1/Isd11 on cysteine may be provided to Isu as persulfide by direct protein
interaction as observed for some bacterial components. A role for frataxin in regulating sulfur
transfer has been proposed in bacteria (60,61). For eukaryotes, the interaction with Nfs1/Isd11 is
not well defined and regulatory functions have not been defined for sulfur transfer. Structural
details of the frataxin-Nfs1/Isd11 interaction also remain to be clarified. The details of the frataxinIsu interaction from the Isu side have not been solved, and these interactions might be competing in
some manner with Isu-chaperone interactions that mediate transfer of the cluster intermediate to
apoproteins.

Is Friedreich’s ataxia a disease of Fe-S cluster assembly?
If Friedreich’s ataxia is caused by frataxin deficiency and frataxin mediates Fe-S cluster assembly,
the question arises whether the disease is caused by Fe-S cluster deficiency. As far as is known,
neither the cellular phenotype nor the human disease phenotype can be explained by deficiency of a
single Fe-S cluster protein. Perhaps it is the combined effects from decreased activities of many Fe-S
cluster proteins that produces the peculiar tissue specific effects characteristic of the disease. Also
the degree of frataxin deficiency may be important for producing the unique cellular disease
phenotypes. Complete lack of frataxin is lethal for growing mammalian cells, and somewhere
between 20-30% is needed for normal growth. In cells with these decreased levels of frataxin, some
Fe-S cluster proteins are deficient and iron accumulates in mitochondria as in the human disease
(16).

In humans, effects of frataxin deficiency are likely to be buffered to different degrees in
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different tissues depending on redundancy with other proteins and tissue specific needs. The
recently demonstrated role of mitochondrial ferritin and its ability to mitigate the effects of frataxin
deficiency might be important in this regard (59), and thus red cell precursors which have the
ability to express mitochondrial ferritin in some settings perhaps would not be as affected by
frataxin deficiency as other tissues e.g. large bore sensory neurons. An inherited disease ascribed to
Isu deficiency has been described, and this is characterized by some degree of Fe-S cluster deficiency
and iron accumulation in affected tissues (62,63). Given the close functional association of frataxin
and Isu, one might expect that the human deficiencies would phenocopy each other. However in
Friedreich’s ataxia, a unique tissue distribution targets dorsal root ganglia, cerebellum, and heart
muscle. In the Isu deficiency disease, by contrast, the features are skeletal muscle swelling and
exercise intolerance; neurodegeneration is not a feature. Thus Isu deficiency and frataxin deficiency
in humans bear some resemblance but the tissue specificities are distinct with the differences still
unexplained.
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